ReviewJournal of clinical medicine2022
Pharmacologic Management for Ventricular Arrhythmias: Overview of Anti-Arrhythmic Drugs.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Idiopathic Ventricular Fibrillation Triggered by Purkinje-Related Extrasystoles: State-of-the-Art and Novel Therapeutic Approaches.Journal of cardiovascular electrophysiology · 2026Review
- Closed-loop bioelectronic block of stellate ganglia reduces neurotransmitter release and improves recovery following programmed ventricular pacing.Frontiers in bioengineering and biotechnology · 2026Article
- Knowledge, attitudes, and practices regarding premature ventricular contractions among patients: a cross-sectional study.Frontiers in public health · 2026Article
- Prognostic Value of Antiarrhythmic Drug Suppression of Electrical Storm Prior to Ventricular Tachycardia Ablation.Journal of cardiovascular electrophysiology · 2025Article
- Management of Arrhythmic Mitral Valve Prolapse: Potential Impact and Current Evidence.Reviews in cardiovascular medicine · 2025Review
- Gene Therapy for Cardiac Arrhythmias: Mechanisms, Modalities and Therapeutic Applications.Medical sciences (Basel, Switzerland) · 2025Review
- Liquid metal-based stretchable bioelectronic fiber for electrical stimulation and drug delivery in minimally invasive cardiac therapy.APL bioengineering · 2025Article
- Opto-sensing of sotalol using parafilm and poly(methyl methacrylate) micro-plates decorated by silver nanoparticles: state-of-the-art for one-drop pharmaceutical analysis.RSC advances · 2025Article
- Ablation of Ventricular and Atrial Arrhythmias in the Era of Cardiac Magnetic Resonance.Echocardiography (Mount Kisco, N.Y.) · 2025Review
- Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system.Frontiers in pharmacology · 2025Article
- Review
- A cross species thermoelectric and spatiotemporal analysis of alternans in live explanted hearts using dual voltage-calcium fluorescence optical mapping.Physiological measurement · 2024Article
- Experimental Studies on the Effect of Expired Amiodarone Drug (EAD) as a Corrosion Inhibitor on Mild Steel in 1 M HCl.Materials (Basel, Switzerland) · 2024Article
- Efficacy of prescribing Inderal for polymorphic ventricular tachycardia in a young patient with the normal QT interval: A case report study.SAGE open medical case reports · 2024Article
- Overview of Cardiac Arrhythmias and Treatment Strategies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Correlations between Cardiovascular Risk Factors and Ventricular Arrhythmias Following Primary Percutaneous Coronary Intervention in Patients with ST-Elevation Myocardial Infarction.The journal of Tehran Heart Center · 2023Article
- Novel Arylpiperazine Derivatives of Salicylamide with αInternational journal of molecular sciences · 2022Article
- Catheter ablation versus medical therapy for ventricular tachycardia in patients with ischemic heart disease: A systematic review and meta-analysis of randomized controlled trials.Indian pacing and electrophysiology journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ventricular arrhythmias (Vas) are a life-threatening condition and preventable cause of sudden cardiac death (SCD). With the increased utilization of implantable cardiac defibrillators (ICD), the focus of VA management has shifted toward reduction of morbidity from VAs and ICD therapies. Anti-arrhythmic drugs (AADs) can be an important adjunct therapy in the treatment of recurrent VAs. In the treatment of VAs secondary to structural heart disease, amiodarone remains the most well studied and current guideline-directed pharmacologic therapy. Beta blockers also serve as an important adjunct and are a largely underutilized medication with strong evidentiary support. In patients with defined syndromes in structurally normal hearts, AADs can offer tailored therapies in prevention of SCD and improvement in quality of life. Further clinical trials are warranted to investigate the role of newer therapeutic options and for the direct comparison of established AADs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.